Jecture focuses on designing and contract manufacturing tailor-made, complex cannulas and cannula systems for pharmaceutical and medical applications. Headquartered in Germany, the group consists of the two well-established companies Acti-Med and EUROPIN – both with more than 25 years of experience in cannula manufacturing.

Jecture unites leading players in cannula and needle development and manufacturing for the international medical technology and pharmaceutical industries. It offers reliable, high-quality serial products in significant volumes as well as innovative and sophisticated custom solutions. The group’s products are primarily used for applications in oncology, ophthalmology, diabetic care, and veterinary medicine. Within its product range, the group is working on new concepts for the future of injection technology that will support medical progress and enhance the lives of patients. In addition to advancing precision in cannula and system design, Jecture has significant exposure to high-priority medical domains, such as oncology and pain therapy. Other products it offers include pen cannulas and lancet needles, which address critical needs in various medical applications such as diabetic use.

Gilde Healthcare invested in Acti-Med in 2021 and EUROPIN in 2022 to form a leading integrated manufacturing group for tailor-made cannulas and cannula systems. The joint vision for these companies is to further expand and internationalize the business through organic growth and targeted acquisitions.